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The gene encoding the secondary multidrug trans-
porter LmrP of Lactococcus lactis was heterologously
expressed in Escherichia coli. The energetics and mech-
anism of drug extrusion mediated by LmrP were studied
in membrane vesicles of E. coli. LmrP-mediated extru-
sion of tetraphenyl phosphonium (TPP
1) from right-
side-out membrane vesicles and uptake of the fluores-
cent membrane probe 1-[4-(trimethylamino)phenyl]-6-
phenylhexa-1,3,5-triene (TMA-DPH) into inside-out
membrane vesicles are driven by the membrane poten-
tial (Dc) and the transmembrane proton gradient (DpH),
pointing to an electrogenic drug/proton antiport mech-
anism. Ethidium bromide, a substrate for LmrP, inhib-
ited the LmrP-mediated TPP
1 extrusion from right-side-
out membrane vesicles, showing that LmrP is capable of
transporting structurally unrelated drugs. Kinetic anal-
ysis of LmrP-mediated TMA-DPH transport revealed a
direct relation between the transport rate and the
amount of TMA-DPH associated with the cytoplasmic
leaflet of the lipid bilayer. This observation indicates
that drugs are extruded from the inner leaflet of the
cytoplasmic membrane into the external medium. This
is the first report that shows that drug extrusion by a
secondary multidrug resistance (MDR) transporter oc-
curs by a “hydrophobic vacuum cleaner” mechanism in
a similar way as was proposed for the primary lactococ-
cal MDR transporter, LmrA.
Infections by pathogenic bacteria can often successfully be
treated with antibiotics. A major drawback of the widespread
use of antibiotics, however, is posed by the selection of antibi-
otic-resistant strains. Different mechanisms of antibiotic re-
sistance have evolved which comprise: (i) the enzymatic inac-
tivation of the antibiotics, (ii) the alteration of the drug target,
(iii) the prevention of drug entry by alterations in the cell
envelope, and (iv) the active extrusion of the drugs from the cell
(1). Active drug extrusion can be mediated by specific drug
resistance (SDR)
1 transporters as well as by multidrug resist-
ance (MDR) transporters; the latter systems confer resistance
to a broad range of unrelated toxic compounds (2).
To date, several bacterial drug extrusion systems have been
identified and characterized at the genetic level (for reviews,
see Refs. 1 and 3). The bacterial drug extrusion systems can be
divided into: (i) secondary drug transporters which mediate
drug extrusion in a coupled exchange with protons (4) and (ii)
ATP-binding cassette-type drug transporters that utilize the
free energy of ATP hydrolysis to extrude cytotoxic substrates
(5, 6). The secondary drug transporters are subdivided into two
groups on the basis of their similarity in size and secondary
structure (7). The largest subgroup, termed TEXANs (toxin-
extruding antiporter), consists of integral membrane proteins
with 12–14 putative transmembrane-spanning segments and
an average molecular mass of 45–50 kDa (3, 8–10). The second
subgroup comprises the mini-TEXANs, which share functional
similarity with the TEXANs but are much smaller (12–15 kDa)
and form only four putative transmembrane a-helices (11, 12).
In Lactococcus lactis, two distinct transport systems (LmrP
and LmrA) have been identified which mediate active extrusion
of multiple cationic drugs (13). LmrP is a secondary drug trans-
porter comprising 408 amino acid residues with 12 putative
membrane-spanning segments (14). The protein is homologous
to several drug transporters belonging to the group of TEXANs.
The second multidrug transporter, LmrA, is a 589-amino acid
integral membrane protein and belongs to the ATP-binding
cassette family of drug transporters.
2 Most strikingly, LmrA is
the first example of a bacterial ATP-dependent multidrug ex-
trusion system in which both functional and structural prop-
erties of the human MDR1 gene-encoded MDR transporter
P-glycoprotein are united.
The involvement of the Dp as a driving force for multidrug
extrusion by TEXAN members has not been studied exten-
sively. Instead, this characteristic of TEXANs is based on the
inhibition of drug transport by protonophores like carbonyl
cyanide p-chlorophenylhydrazone and on their structural sim-
ilarity to other secondary transport systems (16–18). We have
now studied the energetics and mechanism of drug transport
by LmrP in membrane vesicles of Escherichia coli expressing
the protein. Evidence is presented that LmrP mediates drug
transport via an electrogenic mechanism in which drugs are
expelled from the inner leaflet of the phospholipid bilayer.
MATERIALS AND METHODS
Growth of the Organisms—Bacterial strains and plasmids used in
this study are listed in Table I. L. lactis strains were grown at 30 °C on
M17 medium (Difco) supplemented with glucose (25 mM) and erythro-
mycin (5 mg/ml) when needed. E. coli was grown aerobically at 37 °C on
Luria Broth (19) with carbenicillin (50 mg/ml) and isopropyl-b-D-thio-
galactopyranoside when needed.
DNA Manipulation and Construction of H-LmrP—General proce-
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24123dures for cloning and DNA manipulations were performed essentially
as described by Sambrook et al. (1989). In order to subclone lmrP, the
gene was amplified from the chromosome of L. lactis MG1363 via the
polymerase chain reaction as described previously (14). The amino-
terminal polyhistidine (His6)-tag containing LmrP derivative H-LmrP
was constructed by subcloning the lmrP containing polymerase chain
reaction fragment in frame with a His6-tag encoding sequence in the E.
coli expression vector pET302 (Manting, van der Does, and Driessen,
submitted), and transformation of ligated DNA to E. coli DH5a. The
different cloning steps were checked by restriction analysis and double-
stranded DNA sequencing using the dideoxy chain-termination proce-
dure (20) and the T7 DNA sequencing kit (Pharmacia Biotech Inc.).
Preparation of Membrane Vesicles—E. coli DH5a was grown aerobi-
cally at 37 °C to an A660 of about 0.8 on Luria Broth supplemented with
carbenicillin (50 mg/ml) plus isopropyl-b-D-thiogalactopyranoside (100
mg/ml) when appropriate. Inside-out (ISO) (21) and right-side-out (RSO)
(22) membrane vesicles were prepared as described and resuspended in
50 mM potassium HEPES (pH 7.0) containing 5 mM MgSO4 (ISO) or in
50 mM potassium phosphate (pH 7.0) containing 5 mM MgSO4 (RSO).
Membrane vesicles were stored in liquid nitrogen.
Purification of H-LmrP—H-LmrP was partially purified via Ni-NTA
(Ni
21-nitrilotriacetic acid)-agarose affinity chromatography (Qiagen
Inc.). Membrane vesicles (5 mg of protein) were solubilized in 3.5 ml of
buffer A (50 mM sodium phosphate (pH 8.0) plus 600 mM NaCl, 10 mM
Tris/HCl, and 20%, v/v, glycerol) plus Triton X-100 (1%, w/v) for 30 min
at room temperature. Subsequently, the mixture was centrifuged (15
min, 350,000 3 g at 4 °C), and the supernatant was gently mixed with
200 ml of a 50% Ni-NTA resin slurry (100 ml of column material) for 30
min at room temperature, after which the suspension was poured into
a column. The column was subsequently washed with 20 column vol-
umes of buffer A plus 0.5% (w/v) Triton X-100 (buffer B), followed by 50
column volumes of buffer B plus 10 mM imidazole, and 5 column vol-
umes of buffer B plus 25 mM imidazole. Finally, H-LmrP was eluted
from the column with 5 volumes of buffer B plus 250 mM imidazole and
the total fraction (500 ml) was collected. The fractions were analyzed by
SDS-PAGE (23).
TMA-DPH Transport in ISO Membrane Vesicles—The amount of
membrane associated TMA-DPH (Molecular Probes Inc., Eugene, OR)
was measured fluorimetrically as described (24). ISO membrane vesi-
cles prepared from E. coli DH5a (0.4 mg of protein/ml) were suspended
in oxygen-saturated 50 mM potassium HEPES (pH 7.5) containing 25
mM K2SO4 plus 5 mM MgSO4.AD p (inside positive and acidic) was
generated by the oxidation of D-lactate via a constitutively expressed,
membrane-associated lactate dehydrogenase (25). The fluorescence de-
velopment upon addition of TMA-DPH (100 nM, final concentration)
was recorded in time using excitation and emission wavelengths of 350
and 425 nm, and slit widths of 5 and 10 nm, respectively.
TPP
1 Accumulation in RSO Membrane Vesicles—TPP
1 accumula-
tion in RSO membrane vesicles was calculated from the external free
probe concentration as recorded by a TPP
1-selective electrode (26). In
competition experiments, ethidium bromide was added prior to TPP
1 to
correct for changes in the electrode output. RSO membrane vesicles
were resuspended in potassium phosphate (pH 6.8) containing 5 mM
MgSO4 to a final concentration of 0.3 mg of protein/ml. A Dp (inside
negative and alkaline) was generated by oxidation of glucose (10 mM)
via the membrane bound pyrroloquinoline quinone-dependent glucose
dehydrogenase of E. coli (25). Pyrroloquinoline quinone was added to a
final concentration of 1 mM.
FIG.1 .Expression of H-LmrP in E. coli and identification of
the protein. Silver-stained 10% SDS-PAGE containing samples of
total membranes (lanes 1 and 2) and Ni-NTA eluates (lanes 3 and 4)
from cells harboring the control vector pET302 (lanes 1 and 3)o rt h e
H-LmrP-encoding vector pHLP1 (lanes 2 and 4). Lane 5, molecular
weight markers; the arrow indicates the position of H-LmrP.
FIG.2 .TPP
1 accumulation in right-side-out membrane vesi-
cles of E. coli DH5a. The accumulation of TPP
1 in RSO membrane
vesicles of E. coli DH5a/pET302 (control) and DH5a/pHLP1 (H-LmrP)
was followed by recording the external free TPP
1 concentration with an
ion selective electrode. Measurements were carried out in potassium
phosphate (50 mM (pH 6.8)) containing 5 mM MgSO4 plus 4 mM TPP
1 at
30 °C. The additions of RSO membrane vesicles (0.3 mg of protein/ml),
2 mM of pyrroloquinoline quinone plus 10 mM of glucose, 1 mM of nigeri-
cin, and 1 mM of valinomycin are indicated by arrows. Reserpine was
included in the phosphate buffer at a final concentration of 10 mg/ml
when indicated in the figure.
TABLE I
Bacterial strains and plasmids
Bacterium/plasmid Relevant characteristics Source/Refs.
Bacterium
L. lactis
MG1363 ML3, plasmid free, Lac
2, Prt (47)
E. coli
DH5a supE44, hsdR17, recA1, endA1, gyrA96, thi-1, relA1, DLacU169 (*80 LacZDM15) Life Technologies, Inc.
Plasmids
pBluescript SKII
2 Ap
R, expression vector Stratagene
pSKLMR3.2 pBluescript SKII
2, carrying ImnP of L. lactis on a 3.2-kb HindIII fragment (14)
pGK13 Em
R,C m
R ,E. coli-L. lactis shuttle vector (15)
pGKLMR3.2 pGK13, carrying ImnP of L. lactis on a 3.2-kb HindIII fragment (14)
pTRC99A Ap
R, pBR322 derivative containing trc promoter Pharmacia
pET302 pTRC99A carrying a His-tag coding region and trc promoter van der Does, submitted for publication
pHLP1 pET302 carrying ImnP on a 1.390-kb NcoI-XbaI fragment This work
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Heterologous Expression of LmrP and Identification of the
Protein—LmrP was heterologously expressed in E. coli strain
DH5a using the plasmid vector pET302 on which LmrP was
transcribed from the trc promoter. To evaluate the expression
of LmrP in E. coli, a His-tag was engineered at the amino
terminus of the protein, yielding H-LmrP, which allows detec-
tion of the protein after purification by nickel-NTA chromatog-
raphy. Fig. 1 shows that H-LmrP corresponds to a protein with
an apparent molecular mass of 35 kDa on SDS-PAGE.
H-LmrP-mediated TPP
1 Extrusion—To asses the functional
expression of H-LmrP in E. coli, TPP
1 efflux by isolated RSO
membrane vesicles was monitored using an ion selective elec-
trode. Generation of a Dc (inside negative) by glucose oxida-
tion, in the presence or absence of the potassium/proton iono-
phore nigericin, resulted in a high accumulation of TPP
1 in
control RSO membrane vesicles (Fig. 2; pET302). The Dc-
driven passive influx of TPP
1 was much lower in RSO mem-
brane vesicles containing H-LmrP (Fig. 2; pHLP1). Impor-
tantly, measurements of Dc by the fluorescent probe DiSC3(5)
(3,39-dipropylthiadicarbocyanine iodide) revealed comparable
values for the control and LmrP containing RSO membrane
vesicles (data not shown), indicating that differences in TPP
1
accumulation are most likely due to active extrusion of TPP
1
via H-LmrP. An enhanced Dc-driven uptake of TPP
1 was ob-
served in pHLP1 RSO membrane vesicles in the presence of
reserpine (Fig. 2), a known inhibitor of LmrP and other MDR
transporters (14, 27). The TPP
1 accumulation in the presence
of reserpine was similar for the control and H-LmrP containing
RSO membrane vesicles. These data show that the decreased
TPP
1 accumulation in pHLP1 RSO membrane vesicles results
from LmrP-mediated TPP
1 extrusion. In previous experiments
we have shown that ethidium bromide is a substrate for LmrP
(14). In accordance with this observation, the accumulation of
TPP
1 in pHLP1 RSO membrane vesicles was enhanced in the
presence of increasing concentrations of ethidium bromide,
whereas TPP
1 accumulation was not affected by ethidium bro-
mide in control RSO membrane vesicles or in pHLP1 RSO
membrane vesicles plus reserpine (Fig. 3). These experiments
demonstrate that H-LmrP is functionally expressed in E. coli.
Energetics of LmrP-mediated Drug Transport—The
H-LmrP-mediated extrusion of TPP
1 in the presence of nigeri-
cin (Fig. 2) indicates that the Dc can function as the sole
driving force for efflux. To study the energetics of LmrP in
greater detail, TMA-DPH transport was measured in ISO
membrane vesicles of E. coli DH5a in which an inversed Dp
(inside acidic and positive) was generated by the oxidation of
D-lactate. TMA-DPH is an amphiphilic, cationic and hydropho-
bic membrane probe (partition coefficient in octanol/water of
2 . 4*1 0
5 ), which is only fluorescent when present in the mem-
brane (28). Therefore, the fluorescence properties of TMA-DPH
can be directly used to follow the concentration of the probe in
the lipid bilayer by means of fluorescence spectrophotometry
(29). TMA-DPH added to pre-energized pHLP1 ISO membrane
vesicles exhibited a rapid increase in TMA-DPH fluorescence,
which was immediately followed by a fluorescence decrease.
These results indicate that TMA-DPH inserts rapidly into the
membrane and, subsequently, translocates from the membrane
into the intravesicular space (Fig. 4). Importantly, TMA-DPH
FIG.3 .Ethidium bromide and TPP
1 compete for LmrP-medi-
ated extrusion. TPP
1 accumulation as function of the ethidium con-
centration was assayed in H-LmrP containing pHLP1 RSO membrane
vesicles (f), pHLP1 RSO membrane vesicles plus reserpine (M), and in
the control pET302 RSO membrane vesicles (l) as described in the
legend to Fig. 2. The maximal TPP
1 accumulation was calculated from
the difference in recorder output before and after dissipation of the
membrane potential with valinomycin.
FIG.4 . TMA-DPH transport in in-
side-out membrane vesicles of E. coli
DH5a. Uptake of TMA-DPH (100 nM, fi-
nal concentration) was followed fluori-
metrically in an aerated buffer containing
ISO membrane vesicles (0.4 mg of pro-
tein/ml) of E. coli DH5a harboring pHLP1
or pET302. The fluorescence development
was assayed in: nonenergized ISO mem-
brane vesicles (a), ISO membrane vesicles
energized with 10 mM of D-(L)-lactate (b),
as b plus 10 mg of reserpine/ml (c), and as
b preincubated with 1 mM of nigericin (d).
Valinomycin was added to a final concen-
tration of 1 mM as indicated (Val).
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upon dissipation of the DpH by nigericin or by dissipation of the
Dc by the potassium ionophore valinomycin. Complete inhibi-
tion of TMA-DPH transport was observed by (i) total dissipa-
tion of the Dp by nigericin plus valinomycin, and (ii) complete
inhibition of LmrP activity by reserpine. In the control ISO
membrane vesicles, TMA-DPH fluorescence was not affected by
dissipation of the Dp or addition of reserpine (Fig. 4). These
experiments clearly demonstrate that both the Dc and the DpH
function as a driving force of LmrP-mediated drug transport.
Kinetics of LmrP-mediated TMA-DPH Transport—The ki-
netics of TMA-DPH fluorescence development upon the addi-
tion to cells is biphasic (24) (see also Fig. 4). The initial fast
phase reflects probe partitioning in the outer leaflet of the
membrane, while the second and slower phase is due to the
transbilayer movement of TMA-DPH into the inner leaflet of
the membrane. In L. lactis Eth
R cells overexpressing the ATP-
dependent MDR-transporter, the initial TMA-DPH extrusion
rate correlates with the amount of probe associated with the
cytoplasmic leaflet (24), suggesting that LmrA extrudes the
TMA-DPH from the inner leaflet of the lipid bilayer. As shown
in Fig. 5A, similar results are obtained when L. lactis cells are
used that overexpress LmrP. The initial rate of TMA-DPH
extrusion increases in the course of probe flipping from the
outer to the cytoplasmic leaflet of the membrane, whereas the
steady-state TMA-DPH fluorescence level remains the same
(Fig. 5A). The initial TMA-DPH extrusion rate increased in the
course of probe flipping from the external to the cytoplasmic
leaflet of the membrane, whereas the steady-state TMA-DPH
fluorescence levels reached similar values (Fig. 5A). In pHLP1
ISO membrane vesicles, however, the initial transport rates
were identical and independent of the partitioning of TMA-
DPH into the internal leaflet of the inverted membrane system.
The steady-state TMA-DPH fluorescence in this experiment
increased along with the partitioning of TMA-DPH into the
internal leaflet of the membrane (Fig. 5B). The observed kinet-
ics of TMA-DPH transport in whole cells and ISO membrane
vesicles further demonstrate that the rate of TMA-DPH trans-
port depends on the amount of probe associated with the cyto-
plasmic leaflet of the membrane.
DISCUSSION
The energetics and mechanism of LmrP-mediated drug ex-
trusion have been studied in membrane vesicles of E. coli
DH5a in which LmrP was functionally expressed. The lack of
TPP
1 accumulation in pHLP1 RSO membrane vesicles upon
generation of a Dp and the restoration of TPP
1 accumulation,
up to levels observed in the control RSO membrane vesicles,
upon addition of reserpine (Fig. 2) demonstrate that TPP
1
extrusion is LmrP-mediated. In addition, the competition be-
tween TPP
1 and ethidium bromide for LmrP-mediated trans-
port (Fig. 3) is in agreement with our previous conclusion that
multidrug resistance and transport of various unrelated drugs
by L. lactis correlate with the overexpression of LmrP (14). The
slight enhancement of TPP
1 accumulation in the control RSO
membrane vesicles upon addition of reserpine points to the
presence of a low endogenous TPP
1 transport activity in E. coli.
Indeed, genes specifying MDR transporters such as the mini-
TEXAN EmrE (11) and the TEXANs EmrAB (18) and AcrAB
(30) are present in E. coli. Low level expression of one or more
of these proteins might be responsible for the extrusion of
TPP
1. Therefore, in general, data obtained from the transmem-
brane distribution of lipophilic cations like TPP
1, or other
probes that report changes in the Dp (31), have to be treated
FIG.5 .Rate of energy-dependent TMA-DPH extrusion in the
course of TMA-DPH partitioning in the phospholipid bilayer.
Energy-dependent TMA-DPH fluorescence development in cells of L.
lactis MG1363/pGKLMR3.2 (A) and in ISO membrane vesicles of E. coli
DH5a/pHLP1 (B). Cells and ISO membrane vesicles were energized
with 25 mM of glucose or 10 mM of D(L)-lactate, respectively, 3 min prior
to the addition of 100 nM of TMA-DPH or after this addition at the time
points indicated. The dashed line represents the steady-state level of
TMA-DPH fluorescence.
FIG.6 . Proposed mechanism of LmrP-mediated TMA-DPH
extrusion.
Energetics and Mechanism of LmrP 24126with caution as these probes might be recognized by endoge-
nous MDR transporters.
To study the energetics and mechanism of LmrP-mediated
drug transport in greater detail, the fluorescent membrane
probe TMA-DPH was used as a model substrate. Preliminary
studies in whole cells of L. lactis MG1363 expressing LmrP
indicated that TMA-DPH is a substrate for LmrP (Fig. 5A).
3
Consistent with this, LmrP-mediated TMA-DPH uptake could
be measured in pHLP1 ISO membrane vesicles, while no trans-
port was observed in the control ISO membrane vesicles (Fig.
4). The role of LmrP in the transport of TMA-DPH was con-
firmed by the complete inhibition of TMA-DPH transport by
reserpine. The generation of a Dc (inside positive) and/or DpH
(inside acidic) in pHLP1 ISO membrane vesicles resulted in a
significant decrease of TMA-DPH fluorescence and indicated
that LmrP-mediated drug transport is driven by both compo-
nents of the Dp. In view of the charge of the transported drugs,
being monovalent cationic, the data strongly suggest drug
transport via an electrogenic drug/nH
1 (n $ 2) antiport mech-
anism. A similar mechanism was proposed for the mini-TEX-
ANs Smr (12) and EmrE (11). Surprisingly, this mechanism
differs from that of the LmrP homolog TetA, which mediates
the electroneutral exchange of a positively charged tetracy-
cline-metal complex for one proton (32, 33), despite the fact
that LmrP confers resistance to tetracycline as well.
3
The initial rate of LmrP-dependent TMA-DPH transport cor-
relates with the amount of TMA-DPH in the inner membrane
leaflet of whole cells and with the amount of TMA-DPH in the
outer leaflet of ISO membrane vesicles (Fig. 5). Since the outer
membrane leaflet of inversely oriented ISO membrane vesicles
corresponds to the cytoplasmic leaflet in vivo, both observa-
tions rule out the external leaflet of the cytoplasmic membrane
as possible site of drug binding to LmrP. Fig. 6 summarizes our
current view of LmrP-mediated drug transport as depicted for
TMA-DPH. The association of TMA-DPH with lipid bilayers
and the concomitant fluorescence development has been exten-
sively studied (24, 28, 29). Due to the charged TMA moiety,
TMA-DPH is restrictively oriented perpendicular to the surface
of the membrane. Since the TMA-DPH partitioning is highly
asymmetric on a time scale of several minutes, in which the
fast partitioning of TMA-DPH in the external leaflet of the
membrane is followed by a slow passive transbilayer movement
of TMA-DPH to the trans face, it was possible to follow the
redistribution of the probe over both membrane leaflets. As was
shown previously, the passive release of TMA-DPH from the
membrane into the aqueous space is a slow process (24), sug-
gesting the presence of an energy barrier at the membrane
water interface. This notion is consistent with the slow desorp-
tion of phospholipids from the vesicle surface (34). In terms of
MDR, the slow passive release from the membrane of am-
phiphilic cationic drugs would favor a mechanism in which
drugs are directly transported from the cytoplasmic leaflet of
the membrane into the external medium. Indeed this is what is
observed for the initial LmrP-mediated TMA-DPH transport
into ISO membrane vesicles. A fluorescence decrease rather
than an increase is observed when LmrP is active (Fig. 5B). The
latter would be expected when drugs are actively translocated
from the cytoplasmic to the external leaflet of the membrane
followed by passive diffusion into the external medium.
LmrP-mediated TMA-DPH extrusion from the inner leaflet
into the external medium is consistent with the “hydrophobic
vacuum cleaner” model (35–39) which predicts that hydropho-
bic drugs are most efficiently transported from the compart-
ment where the transporter encounters the highest substrate
concentration, i.e. from the membrane. Our studies suggest a
role for MDR-type transporters in maintaining membrane in-
tegrity, which is important since several hydrophobic com-
pounds are known to be toxic at the membrane level (40, 41).
Interestingly, the mechanism of drug extrusion by LmrP is
similar to that of the ATP-dependent drug transporter LmrA of
L. lactis (24). This shows that despite of a different mechanism
of energy coupling to drug transport (Dp versus ATP hydroly-
sis), these nonhomologous proteins may share similar struc-
tural features involved in drug extrusion from the cytoplasmic
leaflet of the membrane. These features are likely to be present
in other MDR transporters as well, including the human P-
glycoprotein (42–46).
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